A 21 year old man in New York has been cured of sickle cell anemia following treatment with a pioneering gene therapy, according to his doctors.
New York resident Sebastien Beauzile was treated with a pioneering new gene therapy approach called Lyfgenia, developed by biotech company Bluebird Bio. Mr Beauzile received the treatment on December 17th 2024 and has not had any symptoms of sickle cell anemia since, leading his doctors to believe that the treatment has likely cured the disease.
"Sickle cell is a debilitating, often-overlooked disease. But treatments like Lyfgenia are changing that," said Jeffrey Lipton, MD, chief of the division of pediatric hematology/oncology & stem cell transplant at Cohen Medical Center in Queens, New York.